Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test

Xu, Xueying; Su, Yang; Song, Ruixiang; Yang, Sihua; Ai, Wensi; Wu, Xiaofei; Liu, Hongbo

doi:10.1007/s12072-015-9643-z

Cited by 29 publications

(22 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In two patients, whose fibrosis stage was at a baseline of S3 and S6, respectively, fibrosis regressed to stages S2 and S5 at 24 months of therapy (Table 3). Previous studies (Xu et al, 2015) in Asian cohorts have suggested that TE is a reliable technique for diagnosing liver fibrosis stages. Our results suggest that liver stiffness, although not exclusively representative of liver fibrosis, may also have value as a diagnostic discriminator for patients needing treatment.…”

Section: Longitudinal Evaluationmentioning

confidence: 96%

Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study

Stasi

Salomoni

Arena

et al. 2017

European Journal of Pharmacology

View full text Add to dashboard Cite

In chronic hepatitis B (CHB) patients, fibrosis assessment during antiviral treatment is a key step in the clinical management. Aim of this study was to evaluate the performance of elastography in assessing fibrosis stage in CHB before and after two years of nucleoside/nucleotide analogues (NUC) treatment in comparison with indirect serum markers. CHB diagnosis was made according to standard criteria. A clinical and virological evaluation was performed at baseline and again at 3, 6, 9, 12 18, and 24 months during treatment. Fibrosis was evaluated by liver biopsy, elastography and indirect serum markers. Of 75 patients, 50 had CHB, HBeAg negative and were deemed eligible for this study. Of these, 22 underwent liver biopsy. Mean histo-morphometric values of fibrotic tissue differed significantly in the stage< S3 vs. stage ≥S3: 2.01±2.62% vs. 12.85±7.31% (p=0.03), respectively. At 18 and 24 months, stiffness values were statistically reduced from those previously observed (P=0.03 and P<0.001). At 24 months the values of APRI, FIB-4 and LOK were not different from baseline values, while the value of FORNS score at 24 months was the only one statistically reduced. In two patients with fibrosis stage S3 and S6, respectively, fibrosis regressed to stage S2 and S5. In conclusion, the results of the present study show that liver histology, stiffness and FORNS score improve significantly during a long-term follow-up of HBV patients successfully treated with NUC. These results strongly suggest that the non-invasive evaluation of liver fibrosis represents a key step in the management and treatment of chronic HBV hepatitis.

show abstract

Section: Longitudinal Evaluationmentioning

confidence: 96%

Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study

Stasi

Salomoni

Arena

et al. 2017

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…Other articles [37][38][39][40][41][42] have confirmed the performance of the method, yielding AUROC values raging between 0.80 and 0.90 (for the prediction of significant fibrosis) and liver stiffness cutoffs varying between 6.6 and 8.8 kPa [9,[43][44][45][46][47]. With regard to the prediction of cirrhosis, AUROCs vary between 0.81 and 0.97 and the cutoffs between 9.4 and 13.4 kPa [44,45].…”

Section: Chronic Hepatitis B (Chb)mentioning

confidence: 74%

Noninvasive Assessment of Diffuse Liver Diseases Using Vibration-Controlled Transient Elastography (VCTE)

Lupșor-Platon¹

2020

Ultrasound Elastography

View full text Add to dashboard Cite

Because of the limitations and invasive nature of liver biopsy, other noninvasive means are being tested for the evaluation of diffuse liver diseases. One of these methods is vibration-controlled transient elastography (VCTE). This chapter reviews the principle of VCTE, the examination technique, the normal range for liver stiffness values, the pathological changes that may influence liver stiffness, as well as the diagnostic performance in several diffuse liver diseases, especially chronic hepatitis C, chronic hepatitis B, nonalcoholic steatohepatitis, and alcoholic liver disease. Apart from the assessment of fibrosis stages, we will also discuss the diagnosis of cirrhosis and its complications as well as other applications of VCTE, reviewing its advantages and limitations.

show abstract

“…We chose an LSM cutoff value of 8.0 kPa in our analysis, which was different from previous validation studies (e.g., 7.2‐8.0 kPa for significant fibrosis) . This was because the focus of our current study was to assess the relationship between LSM and various clinical outcomes (e.g., hepatic events, cardiovascular events).…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B

et al. 2016

View full text Add to dashboard Cite

show abstract

Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test

Abstract: Based on this meta-analysis we claim that liver stiffness measurement using transient elastography has good diagnostic accuracy for predicting single hepatitis B virus-related significant fibrosis and cirrhosis, especially in Asian populations.

Cited by 29 publications

References 45 publications

Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study

Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study

Noninvasive Assessment of Diffuse Liver Diseases Using Vibration-Controlled Transient Elastography (VCTE)

Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B

Contact Info

Product

Resources

About